Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Bayer, Janssen and BMS Unveil Promising Data for Prostate Cancer at ASCO GU

At the American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU), companies have showcased more clinical data in presentations for prostate cancer treatment.

Read More »

J&J acquires Auris Health for $3.4 billion

Johnson & Johnson plunked down $3.4 billion in cash to acquire privately held Auris Health Inc., a company that has developed robotic endoscopic technologies for the treatment of lung cancer.

Read More »

What’s Next: An Innovation Series Powered by Ogilvy Consulting

This webinar, moderated by Ogilvy Consulting’s Ritesh Patel and led by Ogilvy Health’s Angelo Campano and Chris Andrews, will focus on the use of data in healthcare marketing. The webinar will take a closer look at Ogilvy Consulting’s Tripl offering, a proprietary platform that connects data, people and technology, illustrated with real market examples.

Read More »

Agenda 2019 Special Feature: Hungry AIs

Artificial intelligence generated plenty of chatter amongst the pharma marketing intelligentsia in 2018. Will 2019 be the year when the industry fully embraces it as more than just a tactic?

Read More »

Merck, Pfizer combo treatment boosts kidney cancer survival

Merck & Co. Inc. said the combination of the drugmaker’s cancer immunotherapy Keytruda with Pfizer Inc.’s Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with the chemotherapy drug Sutent.

Read More »

Phase 3 ARCHES Trial Shows Xtandi Significantly Improved Radiographic Progression-Free Survival in Men with mHSPC

Pfizer Inc. and Astellas Pharma Inc. announced results from the Phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer (mHSPC).

Read More »

Megaputer Delivers Free Webinar Series on Pharma Analytics

Megaputer Intelligence is hosting a series of live webinars related to data analysis applications for pharmaceutical and life sciences companies beginning on February 6, 2019, and continuing weekly through April 2019.

Read More »

FDA Rejects Alkermes’ Opioid Modulator Treatment for Depression

The U.S. FDA rejected marketing approval of Alkermes’ major depressive disorder treatment ALKS-5461.

Read More »

Merck’s Keytruda tops $2 billion in Q4 2018 sales

Merck & Co.’s cancer immumotherapy Keytruda compiled sales that topped $2 billion in a quarter for the first time, exceeding Wall Street’s lofty estimates and sending the company’s shares up.

Read More »

Medical affairs in the digital age

Evidenced by the move to measure and reimburse providers based on the quality, as opposed to the quantity, of care delivered, the healthcare industry is shifting from a fee-for-service to an outcomes or value-based model.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom